185 related articles for article (PubMed ID: 22234627)
61. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
62. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.
Durbecq V; Di Leo A; Cardoso F; Rouas G; Leroy JY; Piccart M; Larsimont D
Breast Cancer Res Treat; 2003 Feb; 77(3):199-204. PubMed ID: 12602919
[TBL] [Abstract][Full Text] [Related]
63. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
Ogura H; Akiyama F; Kasumi F; Kazui T; Sakamoto G
Breast Cancer; 2003; 10(3):234-40. PubMed ID: 12955036
[TBL] [Abstract][Full Text] [Related]
65. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
[TBL] [Abstract][Full Text] [Related]
66. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.
Minuti G; Cappuzzo F; Duchnowska R; Jassem J; Fabi A; O'Brien T; Mendoza AD; Landi L; Biernat W; Czartoryska-Arłukowicz B; Jankowski T; Zuziak D; Zok J; Szostakiewicz B; Foszczyńska-Kłoda M; Tempińska-Szałach A; Rossi E; Varella-Garcia M
Br J Cancer; 2012 Aug; 107(5):793-9. PubMed ID: 22850551
[TBL] [Abstract][Full Text] [Related]
67. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
68. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
[TBL] [Abstract][Full Text] [Related]
69. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
70. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
[TBL] [Abstract][Full Text] [Related]
71. Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women.
Singhai R; Patil V; Patil A
Asian Pac J Cancer Prev; 2011; 12(1):179-83. PubMed ID: 21517254
[TBL] [Abstract][Full Text] [Related]
72. HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.
Risio M; Casorzo L; Redana S; Montemurro F
Oncol Rep; 2005 Feb; 13(2):305-9. PubMed ID: 15643516
[TBL] [Abstract][Full Text] [Related]
73. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
74. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
76. HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
[TBL] [Abstract][Full Text] [Related]
77. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
78. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
Desmedt C; Sperinde J; Piette F; Huang W; Jin X; Tan Y; Durbecq V; Larsimont D; Giuliani R; Chappey C; Buyse M; Winslow J; Piccart M; Sotiriou C; Petropoulos C; Bates M
Diagn Mol Pathol; 2009 Mar; 18(1):22-9. PubMed ID: 19214112
[TBL] [Abstract][Full Text] [Related]
79. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
Dal Lago L; Durbecq V; Desmedt C; Salgado R; Verjat T; Lespagnard L; Ma Y; Veys I; Di Leo A; Sotiriou C; Piccart M; Larsimont D
Mol Cancer Ther; 2006 Oct; 5(10):2572-9. PubMed ID: 17041102
[TBL] [Abstract][Full Text] [Related]
80. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]